Lay Summary Despite being a rare adverse event, Guillain-Barré syndrome should be a differential diagnosis in patients taking tumor necrosis factor alpha (TNF-α) inhibitors who develop neurological events. Ustekinumab seems to be a safe option after TNF-α inhibitors in these patients.
No takes yet. Share an insight, caveat, or question.
Carvalho et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: